

THE SUMMIT IS CLEAR

once you pass through the clouds

We believe that every patient deserves to know what is driving their cancer and which therapeutics can treat it.





Genomic testing **illuminates** the path

Each tumor has a genomic fingerprint that may help physicians map the best path to overcoming it.

Blazing the trail to make genomic insights actionable

We develop drugs to inhibit the specific alterations that have been identified as drivers of cancer — no matter how rare.


 Our lead candidate seribantumab inhibits tumor growth driven by NRG1 gene fusions.

Seribantumab is being studied in CRESTONE, a Phase 2 trial for patients with solid tumors of any origin that test positive for an NRG1 fusion. Learn more at www.NRG1fusion.com.



OF EVERY CANCER TREATMENT JOURNEY

NRG1 fusions represent **the next summit** in the range of tumor-agnostic precision medicines:





















INVESTORS





EXECUTIVE TEAM

Shawn M. Leland, PharmD, RPh

Founder and Chief Executive Officer

Joseph Ferra

Chief Financial Officer

Amy C. Cavers

VP, Medical Affairs

Tammy Furlong, CPA, PMP

VP, Finance and Accounting

Valerie Malyvanh Jansen, MD, PhD

Chief Medical Officer

Sheila Magil, PhD

VP, CMC and Quality

Brian Sullivan

VP, Corporate Development

Siera Talbott, PhD, PMP

VP, Program Management & Strategic Alliances

BOARD OF DIRECTORS

Steve Elms (Chair)

Managing Partner, Aisling Capital

Shawn M. Leland, PharmD, RPh

Founder and Chief Executive Officer, Elevation Oncology

Lori Hu

Managing Director, Vertex Ventures HC

Colin Walsh, PhD

Partner, Qiming Venture Partners USA

Tim Clackson, PhD

President and EVP, Xilio Therapeutics

Andrew Phillips, PhD

Managing Director, Cormorant Asset Management

SCIENTIFIC ADVISORY BOARD

Lori Kunkel, MD (Chair) LAK505

Sai-Hong Ignatius Ou, MD, PhD

David Ross Camidge, MD, PhDUniversity of Colorado

Siraj M. Ali, MD, PhD

Alex Drilon, MD

MSKCC

EQRx